IRTC iRhythm Holdings, Inc.
FY2025 10-K
iRhythm Holdings, Inc. (IRTC) filed its fiscal year 2025 10-K annual report with the SEC on Feb 19, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Design, development, and commercialization of long-term continuous ambulatory cardiac monitoring (ACM) services using patch-based ECG biosensors with proprietary AI analytics
- • New product emphasis: Introduction of smaller, lighter Zio monitor System with Bluetooth and breathable adhesive, enhancing patient compliance and data quality vs prior Zio XT
Management Discussion & Analysis
- • Revenue $747.1M, up 26% YoY from $591.8M driven by volume increases and new Zio AT customer growth
- • Operating margin -8% in 2025 vs -20% in 2024, loss from operations improved by $58.1M to ($57.4M)
Risk Factors
- • No specific regulatory or legal risk disclosed in the risk factors section
- • No geopolitical or macroeconomic threat with concrete exposure detailed
Financial SummaryXBRL
Revenue
$747M
Net Income
-$45M
Gross Margin
70.6%
Operating Margin
-7.7%
Net Margin
-6.0%
ROE
-29.2%
Total Assets
$1.0B
EPS (Diluted)
$-1.39
Operating Cash Flow
$81M
Source: XBRL data from iRhythm Holdings, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on iRhythm Holdings, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.